HIKAL

Hikal Share Price

₹357.15 -15.15 (-4.07%)

22 Jan, 2025 12:23

SIP TrendupStart SIP in HIKAL

Start SIP

Performance

  • Low
  • ₹356
  • High
  • ₹371
  • 52 Week Low
  • ₹260
  • 52 Week High
  • ₹465
  • Open Price₹370
  • Previous Close₹372
  • Volume143,919

Investment Returns

  • Over 1 Month -5.62%
  • Over 3 Month -3.79%
  • Over 6 Month + 6.98%
  • Over 1 Year + 20.74%
SIP Lightning

Smart Investing Starts Here Start SIP with Hikal for Steady Growth!

Invest Now

Hikal Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 59.9
  • PEG Ratio
  • -5.8
  • Market Cap Cr
  • 4,404
  • P/B Ratio
  • 3.7
  • Average True Range
  • 16.89
  • EPS
  • 5.96
  • Dividend Yield
  • 0.3
  • MACD Signal
  • -7.35
  • RSI
  • 46.66
  • MFI
  • 34.96

Hikal Financials

Hikal Technicals

EMA & SMA

Current Price
₹357.15
-15.15 (-4.07%)
pointer
  • stock-down_img
  • Bearish Moving Average 14
  • stock-up_img
  • Bullish Moving Average 2
  • 20 Day
  • ₹377.76
  • 50 Day
  • ₹383.20
  • 100 Day
  • ₹374.95
  • 200 Day
  • ₹355.59

Resistance and Support

376.38 Pivot Speed
  • R3 399.77
  • R2 393.33
  • R1 382.82
  • S1 365.87
  • S2 359.43
  • S3 348.92

What's your outlook on Hikal?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Hikal Ltd. is a leading Indian company providing pharmaceutical and crop protection solutions, including Active Pharmaceutical Ingredients (APIs), intermediates, and specialty chemicals. It serves global markets, supplying high-quality products to pharmaceutical, agrochemical, and animal health industries.

Hikal has an operating revenue of Rs. 1,821.37 Cr. on a trailing 12-month basis. An annual revenue de-growth of -12% needs improvement, Pre-tax margin of 5% is okay, ROE of 5% is fair but needs improvement. The company has a reasonable debt to equity of 36%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 10% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 44 which is a POOR score indicating inconsistency in earnings, a RS Rating of 66 which is FAIR indicating the recent price performance, Buyer Demand at C which is evident from recent supply seen, Group Rank of 53 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Hikal Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results
2024-08-01 Quarterly Results
2024-05-09 Audited Results & Final Dividend
2024-02-08 Quarterly Results & Interim Dividend
2023-11-02 Quarterly Results
Date Purpose Remarks
2024-09-04 FINAL Rs.0.60 per share(30%)Final Dividend (BC dates changed as RD and XD also revised)
2024-02-20 INTERIM Rs.0.60 per share(30%)Interim Dividend
2023-02-14 INTERIM Rs.0.60 per share(30%)Interim Dividend
2022-09-15 FINAL Rs.0.40 per share(20%)Final Dividend
2022-02-24 INTERIM Rs.1.20 per share(60%)Interim Dividend
View More

Hikal F&O

Hikal Shareholding Pattern

68.85%
2.92%
0%
6.06%
16.65%
5.52%

About Hikal

  • NSE Symbol
  • HIKAL
  • BSE Symbol
  • 524735
  • Managing Director
  • Mr. Sameer Hiremath
  • ISIN
  • INE475B01022

Similar Stocks to Hikal

Hikal FAQs

Hikal share price is ₹357 As on 22 January, 2025 | 12:09

The Market Cap of Hikal is ₹4403.7 Cr As on 22 January, 2025 | 12:09

The P/E ratio of Hikal is 59.9 As on 22 January, 2025 | 12:09

The PB ratio of Hikal is 3.7 As on 22 January, 2025 | 12:09

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23